| Date |
Event |
Presentation |
Speakers |
|
April 10, 2015
|
Asian Oncology Summit 2015
|
Improving the efficiency of cancer drug development: the importance of mechanistic translational studies in early clinical trials
|
Ian Tannock
|
|
|
|
Drug resistance and the tumour microenvironment: inhibition of autophagy as a strategy to improve clinical benefit
|
Ian Tannock
|
|
October 27, 2013
|
Nature - CNIO Cancer Symposium: Frontiers in Tumour Heterogeneity and Plasticity
|
The Development of Predictive Biomarkers in Clinical Trials in the Context of Potential Tumor Heterogeneity
|
Lillian L. Siu
|
|
May 31, 2013
|
ASCO Annual Meeting 2013
|
Career Choices: Options in Academia, Practice, Industry, and Government
|
Lillian L. Siu
|
|
|
|
Lung Cancer in 2013: State of the Art
|
Frances Shepherd
|
|
|
|
Special Session
|
Ian Tannock
|
|
|
|
Special Sessions
|
Lillian L. Siu
|
|
January 22, 2010
|
2010 Gastrointestinal Cancers Symposium
|
Medical oncologist
|
Lillian L. Siu
|
|
October 1, 2009
|
6TH ANNUAL MEETING OF THE INTERNATIONAL SOCIETY OF GASTROINTESTINAL ONCOLOGY (ISGIO)
|
Metastatic Pancreatic Cancer: How to Select the Best Options
|
Malcolm J Moore
|
|
November 15, 2007
|
The Joint Meeting of the 4th ISC International Conference on Cancer Therapeutics and The 7th Princess Margaret Hospital Conference: New Developments in Cancer Management
|
Welcome from PMH
|
Mary K. Gospodarowicz
|
|
|
|
Welcome from ISC
|
Ronald Feld
|
|
|
|
Predictive biomarkers in targeted therapy: Lessons learned
|
Ming-Sound Tsao
|
|
|
|
Session I: Targeted Therapies I
|
Ming-Sound Tsao
|
|
|
|
Going beneath the surface: Novel agents for downstream signaling targets
|
David W. Hedley
|
|
|
|
Targeted therapies for CNS malignancies
|
Warren P. Mason
|
|
|
|
Surgical debate: Is there a role for surgery in stage IIIA NSCLC?
|
Gail E. Darling
|
|
|
|
Session III: Gastrointestinal malignancies
|
Eric X. Chen
|
|
|
|
Targeted therapy of pancreas
|
Malcolm J Moore
|
|
|
|
Liver radiotherapy
|
Laura A. Dawson
|
|
|
|
Welcome to day two
|
Ronald Feld
|
|
|
|
PET/CT for GI tumors
|
Ur Metser
|
|
|
|
Session V: Genitourinary
|
Neil Fleshner, Srikala Sridhar
|
|
|
|
Image guided therapy in prostate cancer
|
John Trachtenberg
|
|
|
|
Targeted radiotherapy in urologic cancer
|
Cynthia Ménard
|
|
|
|
Session VI: Targeted Therapies II
|
Mary K. Gospodarowicz
|
|
|
|
Measuring residual DNA damage in situ as a clinical biomarker of molecular target inhibition in radiotherapy and chemotherapy trials
|
Robert G Bristow
|
|
|
|
Challenges in the design of early phase clinical trials evaluating combinations of radiotherapy and molecularly targeted therapies
|
Anthony Brade
|
|
|
|
Session VII: Malignant Hematology
|
Michael Crump, Hans A. Messner
|
|
|
|
Update on chelation therapy
|
Karen W.L. Yee
|
|
|
|
Management of patients with CML: Beyond imatinib
|
Jeffrey H. Lipton
|
|
|
|
Management of the elderly with acute myeloid leukemia
|
Joseph Brandwein
|
|
|
|
Targeted therapy for lymphoma
|
Michael Crump
|
|
|
|
Targeted therapy in the elderly
|
Lillian L. Siu
|
|
|
|
Welcome to day three
|
Ronald Feld
|
|
|
|
Pharmacogenomic markers in lung cancer
|
Geoffrey Liu
|
|
|
|
Session X: Breast Cancer
|
Natasha Leighl, David Warr
|
|
|
|
Targeted therapy: Targeting tumors or targeting patients?
|
Christine Simmons
|
|
|
|
Session XI: Supportive Care: Managing Toxicities of Targeted Agents
|
Janice Wright
|
|
|
|
Safety and efficacy of rituximab abbreviated infusion
|
Tracy Nagy
|
|
|
|
Session XII: Challenging Cases
|
Ronald Feld, Joseph Mikhael
|
|
|
|
Bladder cancer: Adjuvant versus neoadjuvant therapies
|
Srikala Sridhar
|
|
|
|
Lymphoma: Maintenance therapy
|
Vishal Kukreti
|
|
|
|
Locally advanced lung cancer: Combined modality therapy
|
Andrea Bezjak, Natasha Leighl
|
How We Rank